La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Alvotech a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Alvotech..

Alvotech (NASDAQ:ALVO) Azioni, Catena delle Opzioni

Alvotech

Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.

ALVOPETRO ENEGY LTD by Alvopetro Energy Ltd

Alvopetro Energy Ltd

ALVO MINERALS LTD by ALVO MINERALS LTD.

Wedbush analyst Taz Koujalgi maintains RingCentral (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>) with a Neutral and raises the price target from $36 to $41.

News

Price Target

Analyst Ratings

Wedbush Maintains Neutral on RingCentral, Raises Price Target to $41

Shares of Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) are up 5% this week, trading at $148.83 Friday morning. The stock has gained following Donald Trump's victory in the <a href="https://www.benzinga.com/news/large-cap/24/11/41774549/trumps-big-tech-policies-what-gop-victory-means-for-apple-google-microsoft">2024 U.S. presidential election</a>. 
Trump's return to the White House and a Republican-controlled Senate signal a shift in U.S. economic policy, potentially raising investor optimism around benefits for the semiconductor industry.
What To Know: One driver behind AMD's stock uptick is anticipation of Trump's <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy"> tax policies</a>, which include expanded corporate tax cuts. Analysts predict that lower corporate tax rates could boost AMD's profitability, freeing up capital for reinvestment in its advanced semiconductor production and R&amp;D efforts.
Investors see these policies as advantageous for tech manufacturers like AMD, which face rising costs in developing next-generation chips for data centers, artificial intelligence, and consumer electronics.
Additionally, Trump&#8217;s aggressive trade stance, particularly his focus on tariffs to encourage U.S. manufacturing, could bolster domestic production incentives, a benefit for AMD, which relies on both U.S. and global supply chains.
Read Also: <a href="https://www.benzinga.com/insights/short-sellers/24/11/41781031/peering-into-advanced-micro-devicess-recent-short-interest">Peering Into Advanced Micro Devices&#8217;s Recent Short Interest</a>
What Else: However, while a protectionist stance may reduce competition from foreign manufacturers, there's concern that high tariffs, especially a proposed 60% levy on Chinese imports, could disrupt AMD's supply chain and lead to higher component costs. 
If implemented, these tariffs could impact AMD's pricing flexibility and competitiveness, especially if China retaliates by limiting access to critical raw materials or manufacturing capacity. Still, the prospect of increased U.S. subsidies and lower tax rates under Trump's administration offers short-term optimism for AMD's growth trajectory. 
Analysts caution, however, that long-term challenges persist, including potential inflationary pressures and a volatile trade environment that could strain AMD's cost structure and profitability.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41843928/bitcoin-etfs-saw-record-1-38-billion-inflows-on-thursday">Bitcoin ETFs Saw Record $1.38 Billion Inflows On Thursday</a>
<h2 class="wp-block-heading">How To Buy AMD Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Advanced Micro Devices&#8217; case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, AMD has a 52-week high of $227.30 and a 52-week low of $113.06.

What's Going On With AMD Stock This Week?

BMO Capital analyst Juan Sanabria maintains Retail Opportunity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROIC#NASDAQ">ROIC</a>) with a Market Perform and raises the price target from $17 to $17.5.

ROIC

BMO Capital Maintains Market Perform on Retail Opportunity, Raises Price Target to $17.5

CleanSpark Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) shares are trading higher by 35% to $13.57 this week. Shares of crypto-related stocks are trading higher this week amid strength in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), which reached an all-time high during the U.S. presidential election.
Additionally, CleanSpark announced it <a href="https://www.benzinga.com/pressreleases/24/11/n41714046/cleanspark-releases-october-2024-bitcoin-mining-update">mined 655 bitcoins</a> in October, marking a 32% increase compared to the previous month. As of October 31, the company&#8217;s total bitcoin holdings stood at 8,701.
What To Know: CleanSpark, a bitcoin mining company, benefits directly from Bitcoin&#8217;s performance due to its extensive mining operations, which generate revenue from accumulating and trading the cryptocurrency.
Bitcoin's surge to an all-time high of $75,358 earlier this week has drawn investors to companies with <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41775353/bitcoin-hits-new-all-time-high-as-donald-trump-wins-second-term-what-now">significant crypto exposure</a>, like CleanSpark. With President-elect Donald Trump expected to appoint crypto-friendly regulators, the market anticipates favorable policy shifts, potentially lowering operational costs and enhancing profitability for CleanSpark. 
Trump&#8217;s pro-crypto administration also aligns well with CleanSpark's recent growth strategy, which includes increasing its energy-efficient mining capacity to capitalize on rising Bitcoin demand.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41843182/fed-cuts-rates-but-inflation-remains-elephant-in-the-room">Fed Cuts Interest Rates, But Inflation Remains Elephant In The Room</a>
<h2 class="wp-block-heading">How To Buy CLSK Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Cleanspark&#8217;s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, CLSK has a 52-week high of $24.72 and a 52-week low of $3.46.

$BTC

CLSK

Why Bitcoin-Related Stock CleanSpark Is Up 35% This Week

Wedbush analyst Daniel Ives reiterates Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) with a Outperform and maintains $20 price target.

Reiteration

RIVN

Wedbush Reiterates Outperform on Rivian Automotive, Maintains $20 Price Target

Trading Ideas

SBET

SharpLink Gaming Shares Halted On Circuit Breaker To The Downside, Stock Now Up 36%

BMO Capital analyst Jeremy Mccrea maintains Parex Resources (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PXT#TSX">PXT</a>) with a Market Perform and raises the price target from C$13 to C$14.

TSX:PXT

BMO Capital Maintains Market Perform on Parex Resources, Raises Price Target to C$14

BMO Capital analyst Jeremy Mccrea maintains Kiwetinohk Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/KEC#TSX">KEC</a>) with a Outperform and raises the price target from C$18 to C$20.

TSX:KEC

BMO Capital Maintains Outperform on Kiwetinohk Energy, Raises Price Target to C$20

Wedbush analyst Scott Devitt maintains Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) with a Neutral and raises the price target from $130 to $180.

EXPE

Wedbush Maintains Neutral on Expedia Group, Raises Price Target to $180

<a href="https://x.com/WolfpackReports/status/1854908881161339033" title="https://x.com/WolfpackReports/status/1854908881161339033">https://x.com/WolfpackReports/status/1854908881161339033</a>

Short Sellers

INOD

Wolfpack Research Posts On X "$INOD Regulatory Update per the latest Q: 1. Letter received from the SEC in March requesting $INOD preserve certain documents; 2. DOJ grand jury subpoena received in August; 3. SEC subpoena received in September"

BMO Capital analyst Tom MacKinnon maintains Intact Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/IFC#TSX">IFC</a>) with a Outperform and raises the price target from C$275 to C$290.

TSX:IFC

BMO Capital Maintains Outperform on Intact Financial, Raises Price Target to C$290

Icahn Enterprises L.P. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IEP#NASDAQ">IEP</a>) shares <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">are trading lower on Friday.</a>
The company reported third-quarter earnings per unit of 5 cents, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41839874/icahn-enterprises-l-p-nasdaq-iep-today-announced-its-third-quarter-2024-financial-results" rel="noreferrer noopener">missing the street view of 21 cents</a>. Quarterly sales of $2.22 billion missed the analyst consensus estimate of $2.32 billion.
As of&nbsp;October 31, the firm had approximately&nbsp;$2.3 billion&nbsp;between cash and equivalents at the holding company and the investment funds.&nbsp;
In the third quarter, net income attributable to IEP was $22 million, which is an improvement of $28 million compared to the same quarter last year. Adjusted EBITDA for the third quarter was $183 million, down from $243 million in the prior year&#8217;s quarter.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41845483/taiwan-semiconductor-us-expansion-plans-unfazed-by-trump-win-report" rel="noreferrer noopener">Taiwan Semiconductor US Expansion Plans Unfazed by Trump Win: Report</a>
IEP has proposed that its subsidiary, IEH, initiate a tender offer to buy up to 15 million additional shares of CVR Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVI#NYSE">CVI</a>) common stock at $17.50 per share.
This offer price represents a 6% premium over CVR Energy&#8217;s closing price on November 7, 2024, and a 5% premium over the average price of CVR Energy stock over the last 7 trading days.
IEP said CVR Energy&#8217;s shares are undervalued and sees this as a good investment opportunity. IEP currently beneficially owns, directly and indirectly, 66.3% of the outstanding shares of CVR Energy&#8217;s common stock. If the proposed tender offer were to be fully or over-subscribed, IEP would beneficially own 81.3% of CVR Energy&#8217;s common stock.
As of September 30, Icahn Enterprises&#8217; indicative net asset value decreased by $423 million compared to June 30. This drop was mainly due to a $249 million decline in CVR, a $193 million decrease in Automotive Services, and a $113 million distribution to unitholders, despite a $192 million gain in the investment funds.
Reduces Distribution: On&nbsp;November 6, the Board of Directors of the general partner of Icahn Enterprises declared a quarterly distribution in the amount of&nbsp;$0.50&nbsp;per depositary unit, which will be paid on or about&nbsp;December 26. The company&nbsp;decreased the quarterly distribution from&nbsp;$1.00&nbsp;per depositary unit.&nbsp;
Price Action: IEP shares are trading lower by 7.10% to $11.98 at last check Friday.
Image from Shutterstock
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41819699/roblox-tightens-safety-bans-preteens-from-virtual-social-spaces" target="_blank" rel="noreferrer noopener">Roblox Tightens Safety, Bans Preteens from Virtual Social Spaces</a></li>
</ul>

Earnings

Equities

Guidance

Markets

Movers

General

Icahn Enterprises Hits Rough Patch With Q3 Earnings Miss, Dividend Cut; Eyes Larger Stake In CVR Energy

WIIM

MRVI

Maravai LifeSciences shares are trading lower after the company reported worse-than-expected Q3 financial results and cut its FY24 sales guidance. Additionally, William Blair downgraded the stock from Outperform to Market Perform and Baird cut its price target from $10 to $9.

Wedbush analyst Seth Basham maintains Arhaus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) with a Neutral and lowers the price target from $11 to $10.

ARHS

Wedbush Maintains Neutral on Arhaus, Lowers Price Target to $10

Financial giants have made a conspicuous bullish move on BP. Our analysis of options history for BP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) revealed 12 unusual trades.
Delving into the details, we found 41% of traders were bullish, while 41% showed bearish tendencies. Out of all the trades we spotted, 8 were puts, with a value of $662,350, and 4 were calls, valued at $348,840.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $25.0 to $45.0 for BP over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in BP's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to BP's substantial trades, within a strike price spectrum from $25.0 to $45.0 over the preceding 30 days.
<h3>BP 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731079868_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$12.9</td>
<td>$12.85</td>
<td>$12.9</td>
<td>$42.00</td>
<td>$223.1K</td>
<td>1.2K</td>
<td>173</td>
</tr>
<tr>
<td>BP</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$11.4</td>
<td>$11.35</td>
<td>$11.4</td>
<td>$40.00</td>
<td>$176.7K</td>
<td>1.2K</td>
<td>155</td>
</tr>
<tr>
<td>BP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$6.0</td>
<td>$5.65</td>
<td>$5.65</td>
<td>$25.00</td>
<td>$161.5K</td>
<td>961</td>
<td>286</td>
</tr>
<tr>
<td>BP</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$4.3</td>
<td>$4.2</td>
<td>$4.25</td>
<td>$25.00</td>
<td>$106.2K</td>
<td>3.8K</td>
<td>511</td>
</tr>
<tr>
<td>BP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.39</td>
<td>$1.38</td>
<td>$1.39</td>
<td>$30.00</td>
<td>$66.0K</td>
<td>6.5K</td>
<td>1.1K</td>
</tr>
</tbody>
</table>

<h3>About BP</h3>
BP is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2023, it produced 1.1 million barrels of liquids and 6.9 billion cubic feet of natural gas per day. At the end of 2023, reserves stood at 6.8 billion barrels of oil equivalent, 55% of which are liquids. The company operates refineries with a capacity of 1.6 million barrels of oil per day.
Having examined the options trading patterns of BP, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>BP's Current Market Status</h3>
<ul>
<li>Trading volume stands at 2,282,868, with BP's price down by -2.52%, positioned at $29.06.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 88 days.</li>
</ul>
<h3>Expert Opinions on BP</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $34.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on BP, which currently sits at a price target of $33. 
&#x2A; Reflecting concerns, an analyst from Scotiabank lowers its rating to Sector Perform with a new price target of $36.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for BP with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

BP Options Trading: A Deep Dive into Market Sentiment

BMO Capital analyst Etzer Darout reiterates Genmab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMAB#NASDAQ">GMAB</a>) with a Outperform and raises the price target from $46 to $48.

GMAB

BMO Capital Reiterates Outperform on Genmab, Raises Price Target to $48

Whales with a lot of money to spend have taken a noticeably bullish stance on Cava Group.
Looking at options history for Cava Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 55% of the investors opened trades with bullish expectations and 33% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $106,564 and 6, calls, for a total amount of $202,113.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $85.0 and $140.0 for Cava Group, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Cava Group's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Cava Group's significant trades, within a strike price range of $85.0 to $140.0, over the past month.
<h3>Cava Group 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731079862_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$46.0</td>
<td>$44.8</td>
<td>$46.0</td>
<td>$100.00</td>
<td>$46.0K</td>
<td>3.2K</td>
<td align="right">11</td>
</tr>
<tr>
<td>CAVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$8.2</td>
<td>$7.4</td>
<td>$8.2</td>
<td>$135.00</td>
<td>$41.0K</td>
<td>440</td>
<td align="right">60</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$16.7</td>
<td>$16.5</td>
<td>$16.68</td>
<td>$140.00</td>
<td>$36.7K</td>
<td>1.0K</td>
<td align="right">39</td>
</tr>
<tr>
<td>CAVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$12.2</td>
<td>$11.7</td>
<td>$11.9</td>
<td>$140.00</td>
<td>$35.5K</td>
<td>270</td>
<td align="right">31</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$14.9</td>
<td>$13.1</td>
<td>$13.1</td>
<td>$135.00</td>
<td>$34.0K</td>
<td>629</td>
<td align="right">26</td>
</tr>
</tbody>
</table>

<h3>About Cava Group</h3>
Cava Group Inc owns and operates a chain of restaurants. It is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: CAVA and Zoes Kitchen. The company generates the majority of its revenue from the CAVA segment.
In light of the recent options history for Cava Group, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Cava Group</h3>
<ul>
<li>Currently trading with a volume of 1,240,181, the CAVA's price is up by 0.75%, now at $140.04. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 4 days.</li>
</ul>
<h3>What Analysts Are Saying About Cava Group</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $133.66666666666666.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Neutral rating for Cava Group, targeting a price of $140. 
&#x2A; An analyst from Barclays persists with their Equal-Weight rating on Cava Group, maintaining a target price of $113. 
&#x2A; An analyst from Baird persists with their Outperform rating on Cava Group, maintaining a target price of $148. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Cava Group with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

CAVA

Cava Group's Options Frenzy: What You Need to Know

High-rolling investors have positioned themselves bullish on Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in FCX often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 10 options trades for Freeport-McMoRan. This is not a typical pattern.
The sentiment among these major traders is split, with 50% bullish and 50% bearish. Among all the options we identified, there was one put, amounting to $49,775, and 9 calls, totaling $722,085.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $44.0 to $50.0 for Freeport-McMoRan during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Freeport-McMoRan's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Freeport-McMoRan's significant trades, within a strike price range of $44.0 to $50.0, over the past month.
<h3>Freeport-McMoRan Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731079857_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$2.8</td>
<td>$2.68</td>
<td>$2.75</td>
<td>$50.00</td>
<td>$138.0K</td>
<td>2.8K</td>
<td align="right">521</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$4.45</td>
<td>$4.35</td>
<td>$4.45</td>
<td>$45.00</td>
<td>$129.0K</td>
<td>1.4K</td>
<td align="right">294</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$4.65</td>
<td>$4.55</td>
<td>$4.6</td>
<td>$48.00</td>
<td>$120.9K</td>
<td>231</td>
<td align="right">343</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$3.6</td>
<td>$3.55</td>
<td>$3.6</td>
<td>$44.00</td>
<td>$105.1K</td>
<td>648</td>
<td align="right">307</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$4.65</td>
<td>$4.6</td>
<td>$4.6</td>
<td>$48.00</td>
<td>$78.0K</td>
<td>231</td>
<td align="right">527</td>
</tr>
</tbody>
</table>

<h3>About Freeport-McMoRan</h3>
Freeport-McMoRan Inc is an international mining company. It has organized its mining operations into four primary divisions: North America copper mines, South America mining, Indonesia mining and Molybdenum mines. Its reportable segments include the Morenci, Cerro Verde and Grasberg (Indonesia mining) copper mines, the Rod &amp; Refining operations and Atlantic Copper Smelting and Refining. It derives key revenue from the sale of Copper.
Following our analysis of the options activities associated with Freeport-McMoRan, we pivot to a closer look at the company's own performance.
<h3>Where Is Freeport-McMoRan Standing Right Now?</h3>
<ul>
<li>With a volume of 2,903,867, the price of FCX is down -4.6% at $46.35. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 75 days.</li>
</ul>
<h3>Professional Analyst Ratings for Freeport-McMoRan</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $54.666666666666664.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Neutral rating for Freeport-McMoRan, targeting a price of $55. 
&#x2A; An analyst from Raymond James has decided to maintain their Outperform rating on Freeport-McMoRan, which currently sits at a price target of $57. 
&#x2A; Maintaining their stance, an analyst from Scotiabank continues to hold a Sector Perform rating for Freeport-McMoRan, targeting a price of $52. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Freeport-McMoRan, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Unpacking the Latest Options Trading Trends in Freeport-McMoRan

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer recommended buying Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>), adding that it is &#8220;such a <a href="https://www.benzinga.com/quote/JBL/analyst-ratings">good company.&#8221;</a>
On Sept. 26, Jabil reported better-than-expected fourth-quarter financial results and approved a $1 billion share buyback. Jabil reported fourth-quarter revenue of $6.96 billion, down by 17.7% year-on-year, beating the analyst consensus estimate of $6.59 billion. The print manufacturing company&#8217;s adjusted EPS of $2.30 beat the analyst consensus estimate of $2.22.
When asked about MeiraGTx Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGTX#NASDAQ">MGTX</a>), he said, &#8220;Put it away, speculate. If something great happens, terrific. If not, you won't even notice.&#8221;
On Oct. 15, MeiraGTx released topline data from its clinical bridging study of AAV-GAD for Parkinson's disease, MGT-GAD-025. MGT-GAD-025 is a 6-month, three-arm, randomized, double-blind, sham-controlled study using AAV-GAD drug product manufactured by MeiraGTx at its wholly-owned facilities with its <a href="https://www.benzinga.com/general/biotech/24/10/41339117/small-cap-meiragtx-reveals-encouraging-data-from-parkinsons-study-showing-significant-clinically-">commercial platform process</a>.
SoFi Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) is good, Cramer said.
On Oct. 29, SoFi reported third-quarter adjusted sales of $689.445 million, beating analyst estimates of $632.328 million, according to Benzinga Pro. 
The company reported third-quarter earnings of 5 cents per share, beating estimates of 4 cents per share. SoFi raised its full-year revenue forecast from a range of $2.425 billion to $2.465 billion to a new range of $2.535 billion to $2.55 billion versus estimates of $2.45 billion, according to Benzinga Pro.
Price Action:
<ul>
<li>MeiraGTx shares gained 4.8% to settle at $6.73 on Thursday.</li>
<li>Jabil shares fell 0.3% to close at $137.30 on Thursday.</li>
<li>SoFi shares gained 0.8% to settle at $11.90 during the session.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>
Image: Shutterstock

Long Ideas

Media

MGTX

SOFI

Jim Cramer: This Tech Stock Is A Buy, SoFi Technologies Is Good

Wedbush analyst Seth Basham maintains Tempur Sealy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPX#NYSE">TPX</a>) with a Neutral and raises the price target from $49 to $55.

Wedbush Maintains Neutral on Tempur Sealy Intl, Raises Price Target to $55

Amgen: Growth Is Still A Better Choice

UnitedHealth joins Cigna, CVS in removing AbbVie's Humira from formularies: report

Alvotech application for Prolia/Xgeva biosimilar accepted by EMA

Alvotech (ALVO) has released an update. Alvotech announces the European Medicines Agency's acceptance of their Marketing Authorization Application ...

Alvotech Advances With EU Application Acceptance

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Alvotech (ALVO – Research Report), with a price target of $18.00...

Alvotech (ALVO) Gets a Buy from Barclays

Alvotech (ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), announced that the U.S. Food and Drug Administ...

Teva, Alvotech announce U.S. FDA approval of presentation of SELARSDI

Alvotech (ALVO) has released an update. Alvotech and Teva Pharmaceuticals have received U.S. FDA approval for a new intravenous presentation of SEL...

Alvotech and Teva Secure FDA Approval for SELARSDI

Teva, Alvotech get expanded FDA approval for Stelara biosimilar

FDA accepts Organon BLA for Prolia/Xgeva biosimilar

Alvotech (ALVO) and Advanz Pharma announced that the European Medicines Agency has accepted a Marketing Authorization Application for AVT05, Alvote...

Alvotech announces EMA acceptance of MAA for AVT05

ABBV

ALVO

ALVOW

AMGN

GILD

SDZNY

SDZXF

TEVA

TEVJF

Health Care

Press Releases

European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024

Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®

European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024

Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET

Comments

Alvotech

Alvotech (ALVO) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO